TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of teeth with no pathological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom dimensions of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of canine odorology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Degree of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline in total ADAS-cog score points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of CAD+ patients in RMD+ Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of CAD+ patients in RMD- Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-operative swelling intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum Vitamin D3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thrombosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient Rated Inventory of Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in HBsAg at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostatic Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Graft Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III/IV Irreversible End Organ Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III/IV aGvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Death Within 100 Days Post-Hap-HSCT
Endpoint domain: Mortality/survival
Primary endpoint: Adoption of weekly testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grading of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sinonasal Outcomes Test (SNOT) - 22
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differentiation between post-embolization syndrome and sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfaction assessed by TDI-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfaction self-evaluated and reported in a questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline alveolar bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Liver Biopsy Immunohistochemical Marker of Hepatic Stellate Cell Activation and Collagen Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Fibrosis as Quantified by Morphometric Image Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of dasatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration Adjusted Rate of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Developed Antibodies to Romiplostim
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Developed Antibodies to Endogenous Thrombopoietin
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in lower extremity vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Asymptomatic malaria infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovered Percentage of the Extrapolated Platelet Count at Time 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Days of Platelet Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of medications used for agitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraocular inflammation level (anterior chamber cell count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive score at two years corrected age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in blood oxygenation (PaO2/FiO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Percent Heavy Drinking Days (%HDDs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants performing ArmeoSenso training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Relevant Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local Tolerance at Injection Site Overall Summary: Number of Participants With no Local Tolerance Event and With a Mild, Moderate and Severe Local Tolerance Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Volumetric/Dosimetric Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Jeopardized myocardium size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Parenting Stress Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and Severity of Safety Measures
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hamilton Depression Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale of Pain Intensity (VASPI)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Initial and maximal systolic blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial occlusion pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial and maximal tourniquet pressures (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tourniquet time (minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of CCR2 expression in PDAC tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of response to standard of care chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of response to CCR2-directed therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required for functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occupational Therapy Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Short Physical Performance Battery (SPPB) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 2-month survival rate of null responder to steroid treatment
Endpoint domain: Mortality/survival
Primary endpoint: 6-month survival rate of partial responder to steroid treatment
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative Pancreatic Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in urinary urgency incontinence (UUI) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WOMAC VA 3.0 pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC VA 3.0 physical function subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Global Assessment of Disease Status Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of EBSLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Mean Weekly Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain intensity of postdural headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful production of a Retinal Epithelial (RPE) layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein levels in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Percentage of Participants Who Were Alive and Free From Progressive Disease
Endpoint domain: Mortality/survival
Primary endpoint: Decrease of arterial partial pressure of carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microcirculatory flow index (MIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm motion patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Cerebral Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cervix (Bishop) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants completing the intervention without an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of ACLF measured by CLIF-C ACLF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessment with Verbal Descriptor Scale (VDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Stent Length Upon Deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation Through the End of the Trial
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Induced VT/VF Episode Successful Conversion Rates at Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Induced VT/VF Episode Successful Conversion Rates at 1-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Induced VT/VF Episode Successful Conversion Rates at 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of study ulcers healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal detachment progression/regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants who have disclosed their HIV serostatus to their children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: participants' stage status regarding parental disclosure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in demodex infestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in symptoms and complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of cue induced heroin craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change of negative urinary morphine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral retrobulbar RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inflammation Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antioxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee pain measured on Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain rating difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving proteinuria threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of subjects progressing to end-stage renal disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients receiving therapeutic dose-intensive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of specific autoantigen biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment success in patients with pancreatic fluid collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B transmission rate
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events of INBRX-101
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of adverse events of INBRX-101
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recall under sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject's Rating of Stinging and Burning Sensation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of early-onset neonatal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participant satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Completed visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tracheal cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and epidemiologic characteristics associated with ONJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single nucleotide polymorphisms (SNPs) associated with ONJ risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multifactorial index of ONJ risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Peak AST level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in atelectasis area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Patients with Primary Access Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of liver damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of PET positive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in symptoms of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with non herpes labialis manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bladder symptom prevalence and bother
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prolapse symptom prevalence and bother
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 1 Repetition Maximum (1-RM) Strength Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: benzodiazepine withdrawal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of vancomycin and gentamycin in treating infective endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in quality of MRI studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of days meeting weekly step count target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRRT-filter life span in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival in a 90-day follow-up period
Endpoint domain: Mortality/survival
Primary endpoint: Tumor conversion from CD8 Low to CD8 High
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change from baseline in the MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mean diastolic, systolic, and combined diastolic and systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent of patients with adequately controlled BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morbidity associated with surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Session-level Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Survival on Device
Endpoint domain: Mortality/survival
Primary endpoint: Changes in burnout levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in mood disturbances
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue status
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Global improvement on a five point scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: glutamine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Facial Coding System (NFCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment assessed by change in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fluorescein corneal staining reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Kunming Locomotor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: completion rates of daily assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: completion rates for Remote Therapy Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: % of eligible enrolled youth who complete follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-cancer needs assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of aplindore in RLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of aplindore in RLS
Endpoint domain: Adverse events/effects
Primary endpoint: score on HCAPS survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of PSA recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of serious adverse events related to the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Participation in full range of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of patient enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of mis-alignment of tracheostomy tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Provider Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in cytokine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: normalized T1-weighted signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Volume of Drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oropharyngeal Swallowing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karitane Parenting Confidence Scale (KPCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Quality of Life as Measured on the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Quality of Life as Measured on the Functional Assessment of Chronic Illness Therapy-Palliative Care Scale (FACIT-PAL-14)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life